Stocks股票 / Health Care / PFE

Pfizer · Health Care

PFE US listed · USD美股 · 美元

Pfizer Inc. is an American multinational pharmaceutical and biotechnology corporation headquartered at The Spiral in Manhattan, New York City.辉瑞公司是一家美国跨国制药和生物技术企业,总部位于纽约曼哈顿的螺旋大厦。

Large cap大盘 · $163B Health Care Mixed profile混合特征
$28.67
+$0.26 · +0.92%
52w low52周低 $22.03high高 $29.21
Neutral — no clear edge中性 — 无明显优势 The daily turn is in off a real pullback, but the cycle count is stretched well past its usual window — so this is an UNCONFIRMED new cycle, not a fresh low…日线已在一次真实回调后转向,但周期天数已远超通常窗口——因此这是未确认的新周期,尚非全新低点。请在确认后买入(更高的低点 + 周线转向),而非此处。 As of 2026-09-29截至 2026-09-29
Company intelligence公司情报

The latest call, in context把最新财报放回历史脉络

A synthesized event record across management commentary and recorded metrics. Read as context; verify exact wording in the transcript before relying.综合管理层表述与记录指标形成事件档案。仅供参考;使用前请在电话会原文中核对准确措辞。

Checking latest record正在检查最新记录

Live company record实时公司记录

JavaScript loads the source-bounded event record here. Open Terminal if the live module does not start.JavaScript 会在此加载受来源约束的事件记录。如实时模块未启动,请打开终端。

Continue with full transcript history继续查看完整电话会历史 ↗

Price chart价格图表

daily · interactive日线 · 可交互 Open in Terminal打开终端 ↗
Loading chart…图表加载中…
The interactive chart could not load here.互动图表暂时无法在此加载。 Open the live chart in Terminal在终端中打开实时图表 ↗
Candles, volume and moving averages — pan and zoom inside the chart.蜡烛图、成交量与均线 — 图内可缩放拖动。 MMastermind Terminal — live & interactiveMastermind 终端 — 实时互动 ↗

Technicals技术面

daily bars日线数据 · 2026-09-29
RSI-21 Overbought EntryShort-term Rising TrendLong-term Rising Trend
Momentum (RSI 14)动量(RSI 14) 66
Elevated偏高
vs 50-day average相对50日均线 +6.4% above上方 Uptrend intact趋势完好
vs 200-day average相对200日均线 +11.5% above上方 Long trend up长期向上
Trend strength (ADX)趋势强度(ADX) 32 Strong trend趋势强劲
Volatility波动率 10th percentile第10百分位
These readings feed the stance at the top — one source per number, refreshed nightly.以上读数构成页首的引擎立场 — 每个数字只有一个来源,每晚更新。

Earnings财务业绩

next report下次财报 2026-11-03
36
days to go天后公布

Estimates roughly stable预期基本稳定

Beat expectations 4 quarters in a row连续 4 季度超预期

+13.2% Jun 2026
+5.6% Mar 2026
+15.8% Dec 2025
+31.8% Sep 2025

EPS surprise vs consensus, last quarters每股收益相对预期的超预期幅度(近几个季度) · average平均 16.6%

Valuation估值

Looks cheap vs sector相对行业偏便宜
Multiple指标PFE Sector median行业中位Cheaper than相对便宜
P/E (trailing)市盈率(历史) 20.98x 29.58 74%
P/E (forward)市盈率(预测) 9.9x — —
P/B市净率 1.89x 3.30 81%
P/S市销率 2.60x 3.19 59%
Earnings yield盈利收益率 4.77% 2.56 81%
FCF yield自由现金流收益率 5.57% 4.11 72%
P/FCF市值/自由现金流 17.96x 21.34 67%
"Cheaper than" = share of sector peers trading richer on that multiple.「相对便宜」= 行业中该指标估值更高的同行占比。

Financials财务数据

fiscal years财年
Revenue营业收入 $62.6B2025
20202025
5-yr growth5年复合增速 8.3%
Earnings per share每股收益 $1.362025
20202025
5-yr growth5年复合增速 -4.5%
Free cash flow自由现金流 $9.1B2025
20202025
Net margin净利率
12.4%
FCF margin自由现金流利润率
18.7%
Balance-sheet quality财务体质 5/8 Bankruptcy risk: grey zone破产风险:灰色区 Return on equity股本回报率 9% Clean稳健

Leverage杠杆

Current ratio流动比率1.16

Capital allocation资本配置

Stock-based comp股权薪酬$799.0M
Share count change (1y)股数变化(1年)+0.3%

Debt coming due到期债务

SEC filingsSEC 文件

Debt schedule not loaded yet.到期债务尚未加载。

This panel is still catching up to the SEC filings for this listing. Check back soon — nothing is being estimated in its place.本面板仍在同步该证券的 SEC 文件,请稍后再查看;此处不作任何估算替代。

A cash-flow scenario is unavailable until the filing inputs are verified.报告数据核实前,现金流情景暂不可用。

Capital-need coverage is not available for this issuer yet.该发行人的资本需求覆盖信息暂不可用。

Reported facts remain separate from the cash-flow scenario until identity and filing provenance are confirmed.在确认身份与报告来源之前,已披露事实与现金流情景保持分离。

Research context only — reported figures from SEC filings, not a rating, a signal or investment advice.仅供研究参考 — 数据摘自 SEC 文件披露口径,不构成评级、信号或投资建议。

Why is it moving为何波动

6 checks · nightly六项检查 · 每晚
News新闻 1 recent stories — mixed1 篇最新报道,多空参半
Sector / Theme行业/主题 Big Pharma theme — #8 of 49 themes「大型药企」主题 — 49 个主题中第 8 位
Macro宏观 Long-duration name into a restrictive, rising-real-rate regime → rate headwind.长久期标的进入偏紧、实际利率上行的环境→利率逆风。
Positioning持仓 Insider cluster activity内部人集中交易
Technical技术面 PFE took relative-strength leadershipPFE 取得相对强弱领先

Options positioning期权持仓

as of last close截至上一收盘

Market makers are net long gamma — price pinned near current level做市商净持有正伽玛,价格倾向于在当前水平附近震荡

Expected daily move预期日波动
±1.44%
Expected weekly move预期周波动
±3.22%
Gamma flip伽玛翻转位
$25
25d risk reversal25d风险逆转
0.4%

Flow:资金流向: $6M premium traded; 0% 0DTE; 29 fresh positions; P/C 0.35; ~leans bullish (direction approx)成交权利金 $6M;0DTE占0%;29个新建仓;看跌看涨比 0.35;≈偏看涨(方向近似)

Skew: balanced偏斜:balanced
Call and put walls are plotted on the Trade levels ladder →看涨/看跌期权墙已标注在「交易点位」阶梯上 →

Ownership & smart money持仓与聪明钱

13F

Insider activity:内部人动向: -$0.1M net (0 buyers, 1 sellers)-$0.1M 净值(0 买家,1 卖家)

Concentrated ownership集中持仓

Fund基金Grade评级 Latest move最新动作% of book组合占比As of截至
Fairholme Capital (Berkowitz) A New position新建仓 0.4% 2026-06-30

Signal history信号历史

engine events引擎事件
NEARING A HIGH → BOTTOMING接近高点 → 筑底中 BUY SETUP. A new cycle low likely formed 7 day(s) ago (2026-09-16 @ 27.46): swing low in, price back above the 10-day average — but the weekly timeframe hasn't turned yet, so conviction is partial. Last cycle was left-translated (topped early) — a bearish structural tell买入预备。新的周期低点可能已在 7 天前形成 (2026-09-16 @ 27.46):摆动低点已现,价格重新站上 10 日均线——但周线周期尚未转向,因此信心仅为部分。 上一周期为左移结构(见顶偏早)——属于看空的结构性信号
Sep 24, 2026
PFE took relative-strength leadershipPFE 取得相对强弱领先
Relative strength vs SPY crossed above the 90th percentile of the last 90 days — leadership tends to persist. $28.41.相对标普500的强弱上穿近90日的第90百分位 — 领先往往延续。$28.41。
Sep 23, 2026
NEARING A HIGH → BOTTOMING接近高点 → 筑底中
BUY SETUP买入预备
Sep 22, 2026
PFE StochRSI turned up from oversoldPFE StochRSI自超卖区上行
StochRSI popped back above 20 — the earliest oscillator heads-up that downside momentum is easing. $27.93.StochRSI重回20上方 — 下行动量趋缓的最早预警。$27.93。
Sep 21, 2026
BOTTOMING → NEARING A HIGH筑底中 → 接近高点
TAKE PROFITS止盈
Sep 8, 2026
NEARING A HIGH → BOTTOMING接近高点 → 筑底中
BUY SETUP买入预备
Sep 4, 2026
PFE daily MACD crossed downPFE 日线MACD下穿
The daily MACD histogram turned negative — fast and noisy, context rather than a standalone trigger. $28.45.日线MACD柱状图转负 — 快速且嘈杂,仅作背景。$28.45。
Sep 2, 2026
PFE RSI reached overboughtPFE RSI进入超买
RSI(14) crossed above 70 — stretched to the upside; context, not a timing trigger alone. $29.02.RSI(14)上穿70 — 上行过度;仅作背景,单独不构成择时。$29.02。
Showing the last 15 of显示最近15条,共 4442 signals条信号

Company profile公司档案

Pfizer Inc. is an American multinational pharmaceutical and biotechnology corporation headquartered at The Spiral in Manhattan, New York City.辉瑞公司是一家美国跨国制药和生物技术企业,总部位于纽约曼哈顿的螺旋大厦。

Demand chain:需求链: Contracted bookings (RPO) contracting (-56% YoY to ~$15B, 0.1× revenue) — signed demand locked in ahead of recognition已签约订单(RPO)收缩(同比-56%,约 $15B,覆盖营收 0.1 倍)——已锁定、尚未确认的需求

Style DNA — how it trades vs the market风格基因 — 相对市场的交易特征
Value价值
Below market低于市场
Quality质量
Below market低于市场
Investment资本投入
Above market高于市场
Low volatility低波动
Above market高于市场
Low market beta低市场敏感度
Above market高于市场
Earnings quality盈利质量
Below market低于市场
Short interest空头兴趣
Below market低于市场

AI research briefAI研究简报

generated生成于 2026-09-25

PFE is flashing a short-term bottoming setup (swing low at 27.46, price back above the 10-day and moving averages) but the bigger picture remains mixed; factor tilts favor low-vol/low-beta/investment while value/quality/accruals are negative, and net income growth is slightly negative.

Key drivers主要驱动
  • Short-term cycle bottoming: swing low printed 2026-09-16, price back above the 10-day average, RSI 66, and only -1.2% from the 52-week high
  • Regime is mixed: weekly timeframe has not turned yet, so the daily buy setup has partial conviction
  • Low-vol/low-beta/investment factor scores are positive (low_vol 0.994, low_beta 0.603, investment 0.649); value/quality/accruals are negative
  • Macro tailwind: US net liquidity expanding per the signal
  • Fundamentals: ~$62.6B revenue, 12.4% net margin, 9.0% ROE; net income growth -3.2% and long-term debt ~$61.6B vs CFO ~$11.7B
Key risks主要风险
  • Bigger picture is mixed and weekly timeframe is not confirmed, so the bottoming may fail
  • Prior cycle was left-translated (topped early), a bearish structural tell
  • MACD remains negative despite price above moving averages
  • Quality, accruals, and value factor scores are negative, suggesting weaker fundamental/accounting tilts
  • Net income growth is negative (-3.2%) and long-term debt is high relative to CFO
Upcoming catalysts近期催化剂
  • Watch for a turn in the weekly timeframe to confirm the daily bottoming
  • October seasonality: historically +1.9% average, up 59% of years (n=54), versus September +0.2%
  • Monitor MACD and daily momentum confirming an upward turn
  • Macro sensitivity: continued US net liquidity expansion is a tailwind; a reversal would weaken the setup
Research context only — not a signal, not advice. This is an AI-generated reading of one stock's PUBLIC, already-computed context (its cycle/technical state, cross-sectional factor scores, SEC fundamentals, and recent public news). It does NOT feed any score, signal, ladder call or position size, and it can be wrong or overconfident. The mechanical engine never sees it. Verify every claim against the deterministic analysis on the same page. No holdings or watchlist information is used.

Recent news最新动态

The whole US universe — S&P 1500 and Russell 2000 — read nightly.覆盖标普1500与罗素2000全部成分股 — 每晚更新解读。

Signals, options positioning, smart-money moves and factor DNA — the same engine that wrote this page covers 2,700+ US stocks.信号、期权持仓、聪明钱动向与因子基因 — 撰写本页的引擎覆盖2700多只美股。

Browse all stocks浏览所有股票 Open Terminal打开终端

Research context only — not investment advice. Past patterns do not guarantee future results.仅供研究参考,不构成投资建议。历史规律不代表未来表现。

Data through数据截至 2026-09-29 · regenerated nightly每晚更新 · Generated生成于 2026-09-29 06:10 UTC · All coverage所有股票 · Analyzer分析器